Advanced Reagents for Transcription Factor Drugging – From DNA-Binding Assays to Targeted Protein Degradation Strategies
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TBX1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TBX1 T-box Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed. |
View TBX1 Products |
| Gene Delivery | TBX1 Promise-ORF Lentivirus Full-length ORF for stable cell line construction. CMV promoter, Puromycin selection. |
View TBX1 Products |
| Validator | TBX1 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. Sequence Verified. |
View TBX1 Products |
| Mutant Panel | TBX1 Dominant Negative Mutants (R122G, H194Q) Verified by Mass Spec. For mechanism studies. |
View TBX1 Products |
| Related Target: TBX2 | T-box Transcription Factor 2 Oncogenic paralog – potential compensation mechanism |
View TBX2 Products |
| Related Target: TBX3 | T-box Transcription Factor 3 EMT pathway partner – combinatorial targeting opportunity |
View TBX3 Products |
| Related Target: NKX2-5 | NK2 Homeobox 5 Cardiac development interaction partner – structural biology reference |
View NKX2-5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | High-titer Lentivirus (>10^8 TU/mL) for stable overexpression in HEK293 and cancer cell lines; enables cellular PPI and DNA-binding assays |
| Transcription Factor Solubility/Aggregation | T-box domain (aa 123-224) expressed in HEK293 with native glycosylation context; >95% purity by SEC-HPLC; monodisperse peak guaranteed |
| DNA-Binding Specificity Validation | Wild-type vs. DNA-binding deficient mutants (R122G) available as matched pair for EMSA and AlphaScreen controls |
| Off-Target Family Screening | T-box family panel (TBX1, TBX2, TBX3, TBX5, TBX20) with >90% sequence homology domains available for cross-reactivity assessment |
| Compound Permeability Testing | Nuclear-localized lentiviral expression system with NLS tag; validated for high-content imaging assays |
Live TBX1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Transcription Factor Inhibitor Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The targeting of TBX1 represents a frontier in transcription factor drug discovery. Historically considered "undruggable" due to its intracellular localization and lack of enzymatic active sites, TBX1 is now emerging as a viable target through novel modalities including PROTACs (Proteolysis Targeting Chimeras), molecular glues, and allosteric inhibitors disrupting DNA-binding or cofactor interactions.
Current activity centers on oncology applications, particularly in triple-negative breast cancer (TNBC) where TBX1 drives metastasis and epithelial-mesenchymal transition (EMT). Unlike kinase inhibitors, TBX1-directed therapies require distinct assay paradigms focusing on protein-protein interactions (PPIs) and protein-DNA binding rather than catalytic activity.
As the industry pivots toward transcription factor targeting, TBX1 serves as a model system for T-box family drug development. The next wave of R&D emphasizes ternary complex formation assays for degrader development and high-throughput screening for allosteric DNA-binding inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Academic consortia, emerging biotech | Solid Tumors (Breast) | Ternary complex formation (Need high-purity TBX1 + E3 ligase components); Lentivirus for cellular degradation assays |
| Stapled Peptides | Peptide-focused biotech | Metastatic Cancer | Cell permeability validation (Need nuclear-localized lentiviral TBX1 reporter lines) |
| Molecular Glue | Targeted protein degradation companies | Hematologic Malignancies | PPI stabilization assays (Need mutant TBX1 panels with disrupted interfaces) |
| Gene Therapy (siRNA) | RNA therapeutics developers | Developmental Disorders | Knockdown efficiency validation (Need validated siRNA sets with sequence verification) |
Technical Specifications for TBX1 Drug Discovery
Protein Quality Standards: Recombinant TBX1 T-box domain produced in HEK293 cells ensures proper folding of the DNA-binding domain, critical for structural studies and compound screening. Endotoxin levels controlled to <1 EU/µg prevent interference in sensitive cellular transactivation assays.
Cellular Tool Validation: Lentiviral particles containing full-length TBX1 ORF enable generation of stable reporter cell lines with puromycin selection. These lines support high-content screening for compounds disrupting nuclear localization or DNA binding.
Mutant Library Access: Dominant negative mutants (R122G, H194Q) associated with DiGeorge syndrome provide critical controls for DNA-binding deficient phenotypes, essential for distinguishing specific inhibitors from general cytotoxic compounds.